Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 12, 2021

ProterixBio commercially launches serology test for Covid-19

ProterixBio has announced commercial availability of a serology assay for Covid-19 validated for dried blood spots (DBS) from a finger stick.

ProterixBio has announced commercial availability of a serology assay for Covid-19 validated for dried blood spots (DBS) from a finger stick.

The new quantitative Covid-19 test is an update to the SARS-CoV-2 (RBD) IgG Antibody test that was introduced earlier.

Through the company’s high-complexity CLIA testing laboratory, the new assay is being offered as a testing service.

ProterixBio has one of the only Covid-19 serology tests that offer a quantitative measurement of antibody levels linked to neutralising activity. It also has been validated with DBS.

The SARS-COV-2 (RBD) IgG Antibody test identifies antibodies that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

The assay’s output is a numerical value of the antibody levels present and has been linked to neutralisation titer. It enables the results to be interpreted on a standardised basis.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

ProterixBio noted that it has generated validation data in key population segments.

They include children under 18 years, the general adult population aged between 18 to 80 years, and older adults aged 50 to 80 years with multiple chronic conditions, including chronic respiratory disease.

In addition, the test is authorised in various sample types, including serum, EDTA-plasma, heparin-plasma, and lately, dried blood spots from a finger stick.

Quantitative serology tests can evaluate the response a few weeks after Covid-19 vaccination and the longer-term durability of antibody levels.

It will be especially significant for first responders, healthcare workers, other essential workers, and at-risk populations.

ProterixBio president and CEO Michael Miller said: “Measuring and tracking levels of antibodies associated with neutralising activity may help an individual, together with their physician, make better health decisions.

“The ability to perform this test on finger stick samples increases test accessibility by allowing easier, more convenient specimen collection by healthcare providers.”

The SARS-CoV-2 (RBD) IgG Antibody test is offered as a laboratory-developed test (LDT).

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU